Approved For Marketing EXPANDED_ACCESS NCT03025867

Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

Sponsor: Tesaro, Inc.

Interventions Niraparib

Updated 7 times since 2017 Last updated: Apr 13, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Recurrent Ovarian Cancer, this trial is ongoing. The trial is conducted by Tesaro, Inc. and has accumulated 7 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Approved For Marketing
Jul 2024 — Sep 2024 [monthly]

Approved For Marketing
Jan 2021 — Jul 2024 [monthly]

Approved For Marketing
Jun 2018 — Jan 2021 [monthly]

Approved For Marketing
Apr 2018 — Jun 2018 [monthly]

Approved For Marketing

Phase: NA → None

▶ Show 2 earlier versions

Jun 2017 — Apr 2018 [monthly]

Approved For Marketing NA

Status: Available → Approved For Marketing
Feb 2017 — Jun 2017 [monthly]

Available NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tesaro, Inc.

Data source: Tesaro, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.